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Abstract
Purpose Ductal carcinoma in situ (DCIS) is associated
with an excellent prognosis; historical studies have shown
similar levels of psychological distress in patients with
DCIS and with early-stage invasive breast cancer (early-
IBC). It is suggested that these results might have led to
better patient education about prognosis after DCIS. This
study reports the current levels of anxiety, depression, and
health-related quality of life (HRQoL) in DCIS and early-
IBC patients.
Methods DCIS (n = 89) and early-IBC patients, T1-2N0,
(n = 361) were selected from the UMBRELLA breast
cancer cohort. Patient-reported outcomes were prospec-
tively collected before the start of adjuvant radiotherapy
(baseline) and at 3, 6, 12, 18, and 24 months thereafter.
Mixed models were used to compare differences in levels
of anxiety, depression, and HRQoL between DCIS and
early-IBC patients.
Results DCIS and early-IBC patients reported similar
levels of anxiety, which were highest at baseline. Depres-
sion scores were comparable between groups, also after
stratification by use of adjuvant chemotherapy. The pro-
portion of patients reporting high-risk depression scores
(i.e., Hospital Anxiety and Depression Sale score[8) was
significantly higher among patients with DCIS at 6, 12 and
18 months, and this proportion increased over the first
18 months. Health-related quality of life was comparable
between both groups.
Conclusion Severe depression scores are more common in
DCIS patients, despite their excellent prognosis. These
results suggest that further improvement of patient educa-
tion and effective patient doctor communication about the
prognostic differences between patients with DCIS and
invasive breast cancer is still highly needed.
Introduction
Ductal carcinoma in situ (DCIS) and early-stage invasive
breast cancer (early-IBC) are diagnosed with greater fre-
quency since the implementation of breast cancer-screen-
ing programs [1, 2]. DCIS, which accounts for over 20% of
new breast cancer diagnoses in the United States [3–5], is a
non-invasive condition characterized by neoplastic cells
within the breast ducts, with no theoretic potential for
metastatic spread. With adequate treatment, 10-year breast
cancer-specific mortality following DCIS is very low
(\less than 2%) [6–8], while 10-year breast cancer-specific
mortality for early-IBC is 2–11% [9], resulting in a rapidly
growing population of DCIS survivors.
Despite the lower mortality rate, treatment of DCIS
resembles local treatment of early-IBC. In most Western
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countries, the majority of DCIS patients undergo breast-
conserving surgery with adjuvant whole breast irradiation.
In contrast to patients with early-IBC, axillary staging (i.e.,
sentinel lymph node biopsy) is not indicated in patients
with DCIS [7, 10].
Historically, DCIS patients have consistently reported
similar levels of fear of breast cancer recurrence and death
from breast cancer as women with early-IBC, which can
cause substantial psychological distress [11–17]. Today,
the excellent survival of DCIS is extensively discussed
with the patient by the multidisciplinary team, and innu-
merable online documentation is available to patients on
this matter. It is therefore expected that with the current
knowledge about these misconceptions in DCIS patients,
and with better information about the prognosis, DCIS
patients would report today lower anxiety and depression
than patients with early-IBC. However, no recent studies
have been published comparing patient-reported outcomes
from these groups, receiving modern day treatment in this
era of better patient education.
The aim of this prospective cohort study was to evaluate
the current status of self-reported anxiety, depression, and
health-related quality of life (HRQoL) in the first 2 years
after diagnosis in patients with DCIS and those with early-
IBC receiving treatment between 2013 and 2016.
Methods
This study was conducted within the prospective Utrecht
cohort for Multiple BREast cancer intervention studies and
Long-term evaLuAtion (UMBRELLA) [18]. UMBRELLA
includes patients with invasive breast cancer and patients
with DCIS, referred to the Department of Radiation
Oncology of the University Medical Center (UMC) Utrecht
for adjuvant radiotherapy. All participants were at least
18 years old, and were able to understand the Dutch lan-
guage in written and spoken form. All participants gave
informed consent for the collection of baseline demo-
graphics, tumor and treatment characteristics, clinical fol-
low-up data, and patient-reported outcome measures
(PROs) at regular time intervals. This study complies with
the Dutch law on Medical Research in Humans and was
approved by the Medical Ethical Committee of the UMC
Utrecht, the Netherlands.
For the present study, we selected patients with histo-
logically confirmed early-IBC or DCIS enrolled in
UMBRELLA between October 2013 and February 2016.
All patients with a minimal follow-up of 6 months who
completed at least one follow-up questionnaire were eli-
gible. Patients with recurrent breast cancer after enrollment
were excluded. Tumor type was categorized either as iso-
lated DCIS without micro-invasion or invasive breast
cancer (i.e., invasive lobular, invasive ductal carcinoma, or
DCIS with micro-invasion). The definition for early-IBC
was a clinical and pathological tumor stage (TNM stage) of
T1 or T2 without nodal involvement after axillary staging
of N0 (i.e., negative sentinel node or negative axillary
lymph node dissection).
All patients underwent breast cancer treatment by either
undergoing mastectomy or breast-conserving surgery fol-
lowed by whole breast irradiation varying from minimal 16
fractions of 2.66 Gy, 21 or 23 fractions of 2.17 or 2.03 Gy
with simultaneously integrated 0.49 or 0.63 Gy boost,
respectively. Depending on patient and tumor characteris-
tics (e.g., young age, tumor size, tumor grade, estrogen
receptor status, HER2 receptor status), patients with early-
IBC were treated with chemotherapy, immunotherapy, and/
or hormonal therapy to minimize the risk of recurrence.
Clinical data were obtained from the Netherlands Can-
cer Registry (NCR), part of the Netherlands Comprehen-
sive Cancer Organization (IKNL), which prospectively
registers clinicopathological and treatment characteris-
tics[19]. Data on PROs were collected through self-re-
ported questionnaires administered at regular time intervals
and registered within the Patient-Reported Outcomes Fol-
lowing Initial treatment and Long-term Evaluation of
Survivorship (PROFILES)-registry [20]. PROs were col-
lected before the start of adjuvant radiotherapy (baseline)
and at 3, 6, 12, 18, and 24 months thereafter.
Anxiety and depression were assessed using the Hospital
Anxiety and Depression Scale (HADS) [21, 22]. HADS is a
14-item self-rating scale mainly developed to measure the
severity of symptoms of anxiety and depression in non-
psychiatric patients [22]. Items are grouped into two sub-
scales, i.e., the HADS anxiety sub-scale and HADS
depression sub-scale with a range of scores from 0 to 21 in
each sub-scale. Lower scores on the anxiety- and depres-
sion sub-scale represent less symptoms. Based on valida-
tion, cut-off scores were used to categorize anxiety and
depressive symptoms, values of\8 indicated standard
levels of anxiety and depression. With a score of 8–10,
patients were considered to have possible anxiety and
depression, while values greater than 10 indicate a high
likelihood of anxiety or depressive disorders [21–23].
Health-related quality of life (HRQoL) was assessed
using the European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) [24]. Scores were generated in accordance with
EORTC QLQ-C30 guidelines [25].
Anxiety and depression and HRQoL scores of DCIS and
early-IBC patients were compared to an age-matched
female Dutch reference population without a history of
breast cancer [20].
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Statistical analysis
Categorical data were summarized using frequencies and
percentages. Continuous data were summarized using
means and standard deviations. The Chi-Square test was
used to compare differences in proportions between DCIS
patients and patients with early-IBC.
To compare anxiety and depression scores and HRQoL
between the two groups over time, linear mixed models for
repeated measures were used, which take into account the
correlation between the measurements within subjects. An
autoregressive covariance structure was used for the mixed
model to account for the correlations among observations,
supposing that correlations are higher between measure-
ments that were closer together than time-points further
apart (i.e., decline exponentially) [26]. We included a
random intercept per patient, which takes baseline PRO
differences among patients into account. As fixed effects
we entered time since enrollment (categorical), group
(early-IBC and DCIS), age (continuous), and the interac-
tion between time and group. Between-group effects were
modeled using outcome measurements of anxiety and
depression obtained at baseline and at 6, 12, 18, and
24 months. For HRQoL, an additional measurement was
taken at 3 months. Results were presented as estimated
marginal means and mean differences (MD). We per-
formed a stratified mixed model analysis to compare
patients with DCIS and those with early-IBC patients
without systemic treatment. All statistical tests were
2-sided and performed at a significance level of 0.05.
Statistical analyses were performed with Statistical Pack-
age for Social Sciences (SPSS) software (IBM SPSS
Statistics for Windows, Armonk, NY: IBM Corp.)
Results
In total, 522 patients with primary DCIS or early-IBC were
enrolled in UMBRELLA between October 2013 and
February 2016 (Fig. 1). Responders to at least one follow-
up questionnaire were selected for further analysis (86%,
n = 450). Responders did not differ from non-responders
(14%, n = 72) with respect to age, pathological tumor
stage, axillary surgery, and type of adjuvant radiotherapy
(Supplement Data Table 1). Non-responders were more
often treated with systemic treatment.
From the 450 respondents, 89 (20%) patients were
diagnosed with DCIS and 361 (80%) patients with early-
IBC (Table 1). Mean age at enrollment in UMBRELLA
was similar for both groups (59 years). The majority of
patients (72%, n = 64 for DCIS vs. 57%, n = 206 for
early-IBC) were detected in the context of the national
breast cancer-screening program. In both groups, almost all
patients were treated with breast-conserving surgery (99%,
n = 88 for DCIS; 98%, n = 352 for early-IBC). Whole
breast irradiation consisted of 21 fractions with integrated
boost to the tumor bed for the majority of DCIS patients
(69%, n = 61), while the majority of early-IBC patients
(59%, n = 213) received 16 radiation fractions on the
breast or chest wall without an integrated radiation boost.
In the group of early-IBC, 286 patients (79%) had T1
tumor (microscopic tumor measuring 2 cm or less), 32
patients (8%) received neo-adjuvant systemic treatment,
and 175 (49%) received adjuvant systemic treatment.
For early-IBC patients, mean anxiety and depression
scores slightly decreased over time, while mean anxiety
scores for DCIS patients remained relatively stable up to
the first 18 months of follow-up. In the first 12 months of
follow-up the mean depression score reported by DCIS
patients increased. There were no significant differences in
anxiety and depression scores between DCIS and early-
IBC patients at any time-point (i.e., no significant inter-
action between time and group (DCIS or early-IBC) in any
of the models). This pattern remained similar after strati-
fication for systemic therapy (Fig. 2). For patients with
DCIS a somewhat lower, but non-significant, anxiety score
was observed at 24 months. On the depression sub-scale,
Fig. 1 Flowchart of patients inclusion within the UMBRELLA breast
cancer cohort and questionnaire response rates
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Table 1 Demographics and
disease characteristics of
respondents participating in the
UMBRELLA cohort
DCIS, n (%) Early-IBC, n (%)
Total no. of patients 89 (20) 361 (80)
Age at inclusion, mean (SD) 59 (8) 59 (10)
Breast cancer detected by screening (yes) 64 (72) 206 (57)
Pathological tumor stage
DCIS 89 (100) 2 (1)
T1 0 (0) 286 (79)
T2 0 (0) 54 (15)
Tx 0 (0) 19 (5)
Invasive tumor grade
Grade I 12 (14) 105 (29)
Grade II 35 (39) 149 (41)
Grade III 36 (40) 72 (20)
Unknown 6 (7) 35 (10)
Estrogen receptor status
Negative ND 54 (15)
Positivea ND 302 (84)
Unknown NA 5 (1)
HER2 receptor status
Negative ND 314 (87)
Positive ND 38 (11)
Unknown NA 9 (2)
Neo-adjuvant systemic treatment
None 89 (100) 329 (92)
Chemotherapy and/or immunotherapy 0 (0) 32 (8)
Unknown 0 (0) 0 (0)
Surgical treatment
Breast-conserving surgery 88 (99) 352 (98)
Mastectomy 0 (0) 9 (2)
Otherb 1 (1) 0 (0)
Axillary procedure
No axillary procedure 29 (33) 0 (0)
Sentinel node biopsy 60 (67) 355 (98)
Axillary lymph node dissection 0 (0) 6 (2)
Adjuvant systemic treatment
None 80 (90) 186 (52)
Chemotherapy and/or immunotherapy 0 (0) 30 (8)
Chemotherapy and/or hormonal therapy 0 (0) 46 (13)
Hormonal treatment 0 (0) 98 (27)
Unknown 9 (10) 1 (0)
Radiotherapy treatment
Local 26 (29) 213 (59)
Local with boost tumor bed 61 (69) 144 (40)
Locoregionalc ± boost tumor bed 0 (0) 2 (1)
Unknown 2 (2) 2 (1)
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patients with DCIS report slightly higher scores at 6, 12,
18, and 24 months (Table 2), but these differences were
not significant.
Adjusted HADS scores (for age) from mixed model
analysis were similar for early-IBC patients treated without
systemic treatment and DCIS patients, indicating that
anxiety and depression scores were similar between DCIS
and early-IBC patients, irrespective of systemic treatment
(Supplement data Table 2).
The proportion of patients reporting anxiety scores[8,
indicating an increased likelihood of anxiety disorder, was
not significantly different between DCIS and early-IBC
patients (Fig. 3). For both groups, high-risk anxiety scores
decreased over time. The proportion of patients with DCIS
reporting high depression scores ([8) was significant
higher than the proportion of patients with early-IBC at 6,
12, and 18 months. For patients with DCIS, the proportion
reporting high-risk depression scores increased within the
first 18 months, in contrast to patients with early-IBC
where a decrease in high-risk scores was observed over
time. Compared to the normative population, the propor-
tion of patients reporting high-risk anxiety scores was
higher in both groups in the first 18 months. The proportion
of DCIS patients with high-risk depression scores at 6, 12,
18, and 24 months was higher compared to the normative
population in contrast to the proportion of early-IBC
patients.
Health-related quality of life scores (global health) were
comparable between DCIS and early-IBC patients (Sup-
plement data Table 3). Scores were slightly lower during
treatment (at 3 months), improved at 6 months, and
increased above baseline level as of 12 months in both
Fig. 2 Mean scores on the Hospital Anxiety and Depression Scale
(HADS) of patients with ductal carcinoma in situ, patients with early
invasive breast cancer without (neo)adjuvant systemic treatment and
patients with early invasive breast cancer treated with (neo)adjuvant
systemic treatment at each time-point
Table 1 continued
DCIS, n (%) Early-IBC, n (%)
Median follow-up in months (IQR) 18;15 18;12
Categories may not sum to total N because of missing values. Data may not total to 100% because of
rounding
DCIS ductal carcinoma in situ, Early-IBC early-stage invasive breast cancer, SD standard deviation, ND,
not determined, NA not applicable, HER2 human epidermal growth factor receptor 2, IQR interquartile
range
aEstrogen receptor positive[10%
bTumor was removed during breast reduction
cRadiotherapy on the breast/chest wall and on the axilla levels I-II or I/II–IV
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groups. Health-related QoL scores of DCIS and early-IBC
patients did not differ from the reference population.
Discussion
The proportion of patients with DCIS with high-risk
depression scores, indicating possible depressive disorders,
was significantly higher compared to that of patients with
early-IBC. Patients with DCIS still report similar levels of
anxiety and HRQoL, as compared to patients with early-
IBC, despite abundant literature and online documents
available to patients confirming the excellent prognosis of
DCIS.
To our knowledge, this is the first study to provide
prospectively collected information from a large group of
DCIS and early-IBC patients being treated with modern
day protocol, i.e., better imaging techniques, refined breast
surgery, and more accurate radiotherapy. Furthermore, this
is the only study that directly compares these two patient
groups at different time intervals in the first two years after
surgery. Although on average psychological distress scores
were similar between DCIS and early-IBC patients, the
proportion of patients with DCIS reporting high-risk
depression scores was significantly higher compared to that
of early-IBC patients. For both groups, high-risk anxiety
symptoms scores were high at time of diagnosis and
decreased over time, while the proportion of DCIS patients
with high-risk depression scores increased during the first
18 months. HRQoL scores were similar between DCIS and
early-IBC patients and equivalent to the Dutch reference
population.
Several previous studies showed similar levels of psy-
chological distress and HRQoL in patients with DCIS and
early-IBC. A recent systematic review on 17 studies of
PROs after a diagnosis of DCIS showed persistent exag-
gerated perceptions of the risk of breast cancer recurrence
and death from breast cancer [16]. Higher perceived risk of
recurrence has been associated with general anxiety and
chronic anxiety [4, 16, 27]. Only two studies in breast
cancer patients compared psychological morbidity (i.e.,
anxiety and depression) directly between DCIS and early-
IBC patients [13, 17], while HRQoL between both groups
was compared in 3 studies [12, 13, 15]. In a cross-sectional
study from Rakovitch et al., women with DCIS and early-
IBC treated between 1998 and 1999 expressed similar
levels of anxiety and depression related to their breast
cancer within the first four months after breast surgery [17].
In a Canadian prospective cohort study of 800 breast
cancer patients treated in 2003, women with DCIS
(n = 107) had similar levels of mental health during the
first year after surgery compared to women with early-IBC,
irrespective of the use of adjuvant chemotherapy [13]. InT
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the same study, women with DCIS and early-IBC reported
similar distress levels as the reference population six
months after treatment [13]. Besides anxiety and depres-
sive symptoms, fear of breast cancer recurrence and
exaggerated risk perception was similar in patients with
DCIS and those with stage 1 invasive breast cancer and
persisted for years after diagnosis [14, 29]. Although DCIS
patients were aware of their diagnosis and significantly
better able to differentiate between in situ and invasive
carcinoma than women with early-IBC, they estimated
their risk of recurrence of (invasive) breast disease simi-
larly high as patients with invasive cancer [15, 30, 31]. A
recent cross-sectional study from Denmark on psycholog-
ical distress in DCIS patients only, reported that 20% of
patients reported high anxiety scores (C8 HADS anxiety)
years after surgery. In contrast to our results, they found a
lower proportion (6%) of patients with high depression
scores (C8 HADS depression) 1–3 years after surgery. In
the same study, the need for rehabilitation services was
assessed. Unmet rehabilitation needs were reported by 29%
of the patients [32]. These results indicate that there is a
strong need for appropriate support and rehabilitation ser-
vices even years after treatment for DCIS in this patient
group. Mertz et al. did not compare DCIS patients to
patients diagnosed with invasive breast cancer [32].
Previous studies on HRQoL also found similarities
between DCIS and early-IBC. Longitudinal study from
Jeffe et al. observed similar general health scores in the
first two years after surgery between DCIS and invasive
breast cancer patients (primary stage 0–2A breast cancer
without neo-adjuvant chemotherapy) [15]. In a cross-sec-
tional Dutch population-based study by van Gestel et al.,
HRQoL two to three years after diagnosis was comparable
in women with DCIS and early-IBC [12]. Unexpectedly,
DCIS and early-IBC patients did not only report similar
HRQoL levels but these levels were also comparable to
age-matched control women in both studies [12, 15].This
can be explained by a phenomenon called response shift.
The so-called response shift [33] is characterized by a
change in internal standards when reporting PROs [34, 35].
In a recent longitudinal study by Hart et al. on health-
related quality of life in DCIS patients and controls without
a history of breast cancer, mental quality of life more than
ten years after diagnosis of DCIS declined and was sig-
nificant lower compared to levels shortly after diagnosis
and compared to control group [36].This suggests that
although differences are not present shortly after diagnosis,
differences in HRQoL might appear years after treatment
for DCIS.
Our results suggest that information on prognosis and
tumor biology of DCIS that is provided to patients is still
not sufficient, as DCIS patients still experience similarly
high levels of anxiety as patients with invasive cancer and
more often report high-risk depression scores. Neverthe-
less, our results also suggest that incomplete/inadequate
information on prognosis may not be the main reason for
patients’ psychological stress, as we did not find any dif-
ference between DCIS, early-IBC treated without
chemotherapy, and those treated with chemotherapy. This
is counter-intuitive since those receiving chemotherapy had
a more aggressive treatment required by a higher risk
disease. However, studies suggest that chemotherapy is
independently associated with the risk of depression and
anxiety in patients with invasive breast cancer [37]. It may
Fig. 3 Proportion of patients ductal carcinoma in situ and patients
with early invasive breast cancer with or without (neo)adjuvant
systemic treatment and the Dutch reference population, with high
scores on the Hospital Anxiety and Depression Subscale (HADS)
([8) indicating probable or presence of anxiety or depression
disorders
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be more likely that patients experience some form of post-
traumatic stress, which may be related to the diagnostic
process, treatment, and the feeling of abandonment after
the end of treatment, which is similar for all patients and
independent of the prognostic differences. Levels of
depression scores in patients with DCIS might be higher
due to the fact that these patients have higher unmet needs
for psychological support. It seems plausible that rehabil-
itation programs are offered less often to patients with
DCIS compared to patients with invasive breast cancer
because of the precancerous condition of DCIS, but this
may need further research.
The strength of our study is that–unlike the available
previously discussed historical literature–this study was
performed in a prospective cohort in which PROs of DCIS
patients were directly compared to early-IBC patients. In
addition, it provides data on the current situation after ten
years of knowledge about similar levels of anxiety and
depression in patients with DCIS and early-IBC. Further-
more, it includes longitudinal data in which PROs were
measured regularly within 24 months follow-up.
This study is limited by the fact that we only selected
patients who were referred to the UMC Utrecht for adju-
vant radiotherapy treatment and we did not include DCIS
patients who underwent mastectomy, since there was no
indication for adjuvant radiotherapy in these patients. This
had implications to the generalizability of our results.
Another limitation is that our baseline measurement took
place several weeks after diagnosis (after surgery, before
start of adjuvant radiotherapy). We may have missed a
peak in level of anxiety around diagnosis and surgery,
which might have declined somewhat in both groups as
compared to the preoperative distress level.
In conclusion, the results of this study show that in
recent years severe depression scores are more common in
DCIS patients even months after surgery, despite their
much more favorable prognosis. Anxiety levels and
HRQoL are still similar in patients diagnosed with DCIS
and women with early-IBC. Our results are surprising,
since today, patients have better access to information on
DCIS than a decade ago, and as physicians and nurses are
more aware of the good prognosis of DCIS. Therefore,
there is a need to further explore the cause of this distress
to prevent DCIS patients from unnecessary psychological
distress.
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